All In Biotech

Drug Trial Radar · NCT06987942

Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)

A Randomized, Controlled, Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (Split Virion) in Children Aged 7-12 Years

Last checked: Nov 20, 2026Latest source record: May 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 899 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

899

Actual

Start

Sep 21, 2024

Primary completion

Nov 15, 2024

Study completion Nov 15, 2024

Sponsor

Sponsor type
Industry
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 7 years, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (TIV hereafter). It will also evaluate the safety of simultaneous administration of the two vaccines. The main questions it aims to answer are: * If geometric mean titer (GMT) of varicella zoster vrius (VZV) antibody in the simultaneous administration group is non-inferior to that in the varicella vaccine separate group. * If GMT of hemagglutination inhibition (HI hereafter) antibody in the simultaneous administration group is non-inferior to that in the TIV separate group. Participants in the simultaneous administration group received a single dose of varicella vaccine and TIV simultaneously on day 0. Participants in the separate groups received a single dose of varicella vaccine or TIV on day 0, respectively.

Conditions

  • Varicella
  • Influenza Vaccine

Interventions

  • Varicella vaccine+TIVBiological

    * Varicella vaccine: lyophilized powder, subcutaneous injection * TIV: Inactived, split virion, containing H1N1, H3N2 and BV strains.

  • Varicella vaccineBiological

    lyophilized powder, subcutaneous

  • TIVBiological

    Inactived, split virion, containing H1N1, H3N2 and BV strains.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMT of VZV antibodyTime frame: Day 30 after the vaccination
  2. GMT of HI antibodyTime frame: Day 30 after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial Center for Disease control and Prevention

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.